Bipartisan AGs Urge FDA to Act Against Counterfeit GLP-1 Drugs

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • The National Association of Attorneys General (NAAG) sent a letter on behalf of a bipartisan coalition of 38 state and territory AGs requesting that the FDA act to protect consumers from counterfeit forms of weight loss and diabetes drugs (GLP-1 drugs).
  • In the letter, the AGs explain that counterfeit GLP-1 drugs have entered the U.S. supply chain from foreign sources and that these counterfeits can contain contaminants, other unknown drugs, or dangerously high amounts of active ingredients; that online retailers are illegally selling the active ingredients of GLP-1 drugs to consumers without a prescription, requiring consumers to formulate the medications themselves; and that unsanitary conditions at some pharmacies could lead to serious public health issues.
  • The AGs argue that concurrent federal action will provide the most protection against illegal conduct related to the sale of GLP-1 drugs, and they urge the FDA to exercise its statutory authority through investigations, inspections, and enforcement actions.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Cozen O'Connor

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide